These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33506984)

  • 21. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis.
    Karstarli Bakay OS; Kacar N
    Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
    Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
    Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligelizumab for the treatment of chronic spontaneous urticaria.
    Wedi B
    Expert Opin Biol Ther; 2020 Aug; 20(8):853-861. PubMed ID: 32380864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
    Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
    Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.
    Dortas Junior S; Azizi G; Valle S
    Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531
    [No Abstract]   [Full Text] [Related]  

  • 26. Successful treatment of four types of chronic urticaria with anti-IgE omalizumab in the same patient.
    Nettis E; Di Leo E; Calogiuri G; Foti C; Macchia L
    Ann Allergy Asthma Immunol; 2019 Mar; 122(3):336-337. PubMed ID: 30529714
    [No Abstract]   [Full Text] [Related]  

  • 27. Omalizumab for chronic urticaria in children younger than 12 years.
    Al-Shaikhly T; Rosenthal JA; Ayars AG; Petroni DH
    Ann Allergy Asthma Immunol; 2019 Aug; 123(2):208-210.e2. PubMed ID: 31082483
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria.
    Chiarella SE
    Allergy Asthma Proc; 2019 Nov; 40(6):485-489. PubMed ID: 31690400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
    Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
    Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
    Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
    Front Immunol; 2021; 12():635069. PubMed ID: 33737936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Giordano-Labadie F; Becherel PA; Pralong P; Outtas O; Ruer-Mulard M; Berard F; Greco M; Lacour JP; Debons-Peyroutet M; Pelvet B; Lamirand A; Guillet G
    Eur J Dermatol; 2021 Apr; 31(2):217-224. PubMed ID: 34001470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
    Hayama K; Fujita H; Asai-Sato M; Kawana K; Terui T
    Eur J Dermatol; 2021 Feb; 31(1):100-101. PubMed ID: 33459258
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study.
    Bostan E; Zaid F; Karaduman A; Dogan S; Gulseren D; Yalici-Armagan B; Akdogan N; Ersoy-Evans S; Elcin G
    J Cosmet Dermatol; 2021 Nov; 20(11):3369-3375. PubMed ID: 34599630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases.
    Ayhan E; Öztürk M; An İ; Bekçİbaşi M
    Int J Dermatol; 2021 Feb; 60(2):253-254. PubMed ID: 33332576
    [No Abstract]   [Full Text] [Related]  

  • 35. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
    Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
    Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Belbezier A; Boccon-Gibod I; Bouillet L
    Eur J Dermatol; 2021 Feb; 31(1):86-87. PubMed ID: 33772528
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
    Di Leo E; Calogiuri G; Macchia L; Nettis E
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
    [No Abstract]   [Full Text] [Related]  

  • 38. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria?
    Thiede RM; Fazel M; MacDonald KM; Abraham I
    Expert Opin Pharmacother; 2022 Oct; 23(14):1563-1567. PubMed ID: 36173375
    [No Abstract]   [Full Text] [Related]  

  • 39. Omalizumab for the treatment of chronic urticaria.
    Zuberbier T; Maurer M
    Expert Rev Clin Immunol; 2015 Feb; 11(2):171-80. PubMed ID: 25566680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.
    Cho YT; Fu KT; Yang CW; Chu CY
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.